Abbott Laboratories puts NeuroSearch pain drug into trials  

Abbott Laboratories and NeuroSearch initiate clinical studies of compound ABT-202 for the treatment of pain

Abbott Laboratories and Danish biopharmaceutical company NeuroSearch have initiated Phase I clinical studies of a compound codenamed ABT-202 for the treatment of pain. ABT-202 is the first candidate drug coming from the partnership between the two companies.


In 2000, NeuroSearch and Abbott entered an agreement involving preclinical research to identify new drugs for the treatment of pain and other serious diseases in the central and peripheral nerve systems. Abbott is responsible for the clinical development and commercialization of all compounds emerging from the collaboration. Under the agreement, Abbott provides research funding to NeuroSearch and also will pay milestone payments to NeuroSearch for each successfully developed compound, as well as royalties on sales of marketed compounds resulting from the collaboration. The news is reported on the Copenhagen Stock Exchange website.


In addition to ABT-202, NeuroSearch has compounds in clinical development for Alzheimer’s disease, Parkinson’s disease, and epilepsy and brain damage following stroke. The company has strategic alliances with Abbott Laboratories, Boehringer Ingelheim, GlaxoSmithKline, Pharmexa and Pierre Fabre.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×